**Appendix Table K2. Summary risk of bias assessments: hormone interventions vs. inactive controls in adults with normal cognition**

|  |  |  |  |
| --- | --- | --- | --- |
| Intervention Type | Study | Overall Risk of Bias Assessment | Rationale |
| HRT-estrogen efficacy | Henderson 20161 | Medium/High | Medium attrition (10%) at 2.5 years; high attrition (30%) at 5 years without correction for possible bias; unclear whether outcome assessor was independent |
| Wroolie 20152  Rasgon 20143 | Medium | Medium (16%) attrition for cognitive outcomes; high (30%) attrition for MRI without correction to account for possible bias; participants not blinded to treatment |
| Espeland 20134  Espeland 20105  Coker 20096  Resnick 20097  Resnick 20098  Resnick, 20069, 10  Shumaker 200411  Rapp 200312  (Women’s Health Initiative sub-studies)  Medium | Medium | Medium attrition (rate varies by specific outcome); possible detection bias for some outcomes |
| Gorenstein 201113 | Medium | Medium attrition (19%) without correction to account for possible bias; unclear whether outcome assessor was independent |
| Pefanco 200714 | Medium | Medium (21%) attrition with some analysis to account for possible bias; unclear whether outcome assessor was independent |
| Yaffe 200615 | Low |  |
| **HRT-estrogen + progestin efficacy** | Kantarci 201616  Gleason 2015}17 | Medium (cognitive outcomes)  High (MRI) | Medium attrition (10%) at 2.5 years; high attrition (30%) at 5 years |
| Espeland 20134  Espeland 20105  Coker 20096  Resnick 20098  Resnick 20069  Espeland 200410  Shumaker 200411  Shumaker 200318  Rapp 200312  RCT (Women’s Health Initiative substudies)  USA  Medium | Medium | Medium attrition (rate varies by specific outcome); possible detection bias for some outcomes |
| Davison 201319 | Medium | Attrition (17%) without analysis to account for possible bias; unclear whether outcome assessor independent |
| Alhola 201020 | High | Attrition (>25%) from original randomization without analysis to account for possible bias |
| Maki 200921 | High | High attrition (>25%) without appropriate analysis |
| Tierney 200922 | Low/Medium | Unclear whether outcome assessor independent |
| Grady 200223 | Medium | Medium attrition (20%) without appropriate analysis; unclear whether outcome assessor independent |
| Binder 200124 | High | High attrition (22%) without appropriate analysis; unclear whether outcome assessor independent |
| **DHEA efficacy** | Kritz-Silverstein 200825 | Medium | Randomization not well described; medium attrition (15%) without appropriate analysis; unclear whether outcome assessor independent |
| **HRT-testerone efficacy** | Vaughn 200726 | High | High attrition (33%) without appropriate analysis; unclear whether outcome assessor independent |
| Kenny 200227 | High | Randomization not well described; high attrition (34%) without appropriate analysis; unclear whether outcome assessor independent |
| **SERM efficacy** | Yaffe, 200528  Yaffe, 200129 | Medium | Medium attrition without appropriate analysis; unclear whether outcome assessor independent |
| Nickelsen 199827 | Medium | Randomization not well described; unclear whether outcome assessor blinded and independent |
| **Soy efficacy** | Henderson 201231 | Low |  |
| Gleason 200932 | Medium | Randomization not well described; medium (12%) attrition without appropriate analysis; unclear whether outcome assessor blinded |
| Ho 200733 | Medium | Medium attrition (12%) without appropriate analysis; unclear whether outcome assessor independent |
| Casini 200634 | High | Unclear whether baseline cognitive tests were performed (no baseline data presented); unclear whether outcome assessor independent |
| Kreijkamp-Kaspers 200435 | Medium | Medium attrition (24%) with some analysis; unclear whether outcome assessor independent |
| Kritz-Silverstein 200336 | Low |  |
| **Red clover efficacy** | Maki 200921 | High | High attrition (>25%) without appropriate analysis |
| Howes, 200437 | Medium | Unclear whether outcome assessor blinded and independent; participants may have been unblinded to treatment during crossover |

DHEA=dehydroepiandrosterone; RCT=randomized controlled trial;